PSI Sci

Before you vote › Federal bills

S. 4109: Stem Cell Therapeutic and Research Reauthorization Act of 2026

119th Congress · introduced 2026-03-17 · Health · Latest: Placed on Senate Legislative Calendar under General Orders. Calendar No. 443.

federal

What does this mean?

Official title

Stem Cell Therapeutic and Research Reauthorization Act of 2026

Plain summary

Stem Cell Therapeutic and Research Reauthorization Act of 2026 This bill reauthorizes through FY2031 and revises programs that help patients receive transplants of bone marrow or umbilical cord blood from biologically unrelated donors. These programs are administered by the Health Resources and Services Administration (HRSA). The bill reauthorizes the C.W. Bill Young Cell Transplantation Program. This program supports transplantation of bone marrow and cord blood by increasing the quantities of donations, providing processes for matching and distributing donated materials to patients, and providing related information and research. The bill also expands periodic reviews of the state of stem cell science to specifically include a review of the use of high-quality cord blood units and other emergent technologies to develop new therapies for potential inclusion in the program. Also, the bill reauthorizes and revises the National Cord Blood Inventory program, through which HRSA contracts with qualified cord blood banks to collect and maintain a supply of high-quality units for transplantation through the C.W. Bill Young Cell Transplantation Program. The bill amends the inventory program by (1) changing the inventory goal from 150,000 units to a sufficient supply as determined by HRSA, (2) requiring HRSA to manage the size and composition of the inventory to maximize clinical utility and efficiency, and (3) defining high quality cord blood unit to mean a unit meeting current industry standards and the requirements of the Food and Drug Administration.

Congressional Research Service summary (Reported to Senate), quoted unchanged (nonpartisan). Read the source.

What a vote does

A “Yea” vote

If it passes both chambers and is signed, it becomes law.

A “Nay” vote

If it is not passed, current law stays as it is.

PSI Sci description of the legislative step (not an opinion).

What does this mean? (plain words)

Official text

Stem Cell Therapeutic and Research Reauthorization Act of 2026

Source: Congressional Research Service summary (Reported to Senate)

AI explanation – may be wrong, check the official text

No AI explanation yet. It takes up to a minute to write and is then saved for everyone.

Limited to a few requests an hour per person.

The strongest published arguments

Arguments for (supporters)

Needs sources: no published arguments on this side yet. We only show items backed by a published source. Suggest one.

Arguments against (opponents)

Needs sources: no published arguments on this side yet. We only show items backed by a published source. Suggest one.

Alternatives

Needs sources: no published alternatives yet (for example a different bill, a law instead of an amendment, or keeping current law). We only show items backed by a published source. Suggest one.

Officials and money

Sponsor: Sen. Reed, Jack [D-RI] · 3 cosponsors

Money: No cost estimate published yet. No linked contracts or vendors yet.

Words on this page, explained (1)
Bill
A proposed law. It becomes law only if it passes the legislature and is signed by the president or governor (or a veto is overridden).

Plain meanings written from linked sources. All words.

Sources

Record fed-us-cong119-s4109 · catalog fed-us-congress-bills-cong119 · updated 2026-11-03 by psicol fed-bills